Monitoring pharmaceutical expenditure | Italian Medicines Agency Aifa toggle bar Search Search keywords The Agency The Agency Mission and values Organisation Scientific and Economic Committee for Medicines Support and Coordination Secretariats and Advisory Committees International Collaborations EU Projects Legislation Forms Competition notices Resolutions Tenders and contracts Quality assurance Guarantee Committee Atti di notifica Associazioni dei pazienti AIFA Incontra Contacts Certified email COVID-19 COVID-19 Communications about COVID-19 COVID-19 Vaccines Medicines usable for treatment of COVID-19 disease Use of monoclonal antibodies for COVID-19 Use of antivirals for COVID-19 Monitoring of medicinal products used during the COVID-19 epidemic Clinical Trials - COVID-19 Compassionate Use Programs - COVID-19 Access to medicinal products Access to medicinal products Early access and off-label use Authorisation of medicinal products Medicine shortages Antibiotic medicinal products Biological medicinal products Vaccines Blood derivatives Generic medicinal products Biosimilar medicinal products Orphan medicinal products Advanced therapies Homeopathic medicinal products Allergens Medicinali di origine vegetale Ancillary medicinal substances incorporated in medical devices Safety of medicinal products Safety of medicinal products Pharmacovigilance National Pharmacovigilance Network Adverse Reactions to medicinal products Persons in charge of Pharmacovigilance European Eudravigilance System Accesso alle segnalazioni - ADRreports Regional pharmacovigilance funds Segnali di sicurezza Risk management measures Medicinal products subject to additional monitoring Quality and Inspections Quality and Inspections Quality defects Inspections and authorisations Qualified person Fight of pharmaceutical crime Research and Clinical trials Research and Clinical trials Clinical trials concerning medicinal products EU Regulation on Clinical trials National Observatory on Clinical Trials Registro Studi Osservazionali Comitati Etici Nazionali (CEN) Ethics Committees Coordination Centre Independent clinical research Mappa dei centri di Sperimentazione Clinica Pricing and reimbursement Pricing and reimbursement Negotiation and reimbursement Economic evaluations Monitoring Registers AIFA Notes Lists of Class A and Class H medicinal products Innovative medicinal products Transparency Lists Consumption and pharmaceutical expenditure Consumption and pharmaceutical expenditure The Medicines Utilization Monitoring Centre (OsMed) Governance of pharmaceutical expenditure Monitoring pharmaceutical expenditure Innovation and planning Innovation and planning Innovation and scientific advice Horizon scanning Information and communication Information and communication FarmaciLine Medical and scientific information FAQ Publications Communication campaigns Eventi AIFA Scientific Seminars Press releases Dossier AIFA Mobile APP AIFA APP Firstline AIFA - Antibiotici ABC della Ricerca Clinica Presentations and speeches Public consultations and documents Documents shared with scientific communities Calendario eventi Archivio AIFA data AIFA data OsMed Data Open Data Companies Section Companies Section Requests for authorisation of conferences and meetings Payment of fees and annual duties MA Electronic invoicing Application for reimbursement and pricing Access information Notifica concessionari di vendita Comunicazione prima commercializzazione Open governance Open governance Disposizioni Generali Organizzazione Consulenti e collaboratori Personale Bandi di Concorso Performance Enti controllati Attività e procedimenti Provvedimenti Bandi di gara e contratti Sovvenzioni, contributi, sussidi, vantaggi economici Bilanci Beni immobili e gestione patrimonio Controlli e rilievi sull'Amministrazione Servizi Erogati Pagamenti dell'Amministrazione Opere pubbliche Pianificazione e governo del territorio Informazioni ambientali Interventi straordinari di emergenza Altri Contenuti Monitoring pharmaceutical expenditure Monitoring pharmaceutical expenditure The pharmaceutical expenditure monitoring that AIFA periodically publishes is an essential prerequisite of pharmaceutical care planning activities in Italy. AIFA conducts monthly monitoring of pharmaceutical expenditure data and reports its findings to the Ministry of Health and the Ministry of Economy and Finance at the same frequency. AIFA also verifies whether the expenditure ceilings are exceeded at the national level, both for pharmaceutical expenditure under approved care regime and for direct purchases, as established by the budget law. Monitoring of pharmaceutical spending is conducted on the basis of data of expenditure under approved care regime and Summary Bills of Accounts (DCRs) acquired by Italian regions, as well as on data acquired from the Ministry of Health's New National Information System (SIS) related to drug traceability (Ministerial Decree July 15, 2004). As of January 1, 2022 (Decree Law No. 73 of May 25, 2021), the Fund established in 2017 to contribute to reimbursement to the regions for the purchase of innovative oncology medicines and the Fund established for non-oncology medicines were unified into a single Innovative Medicines Fund whose allocation is 1,000 million euros, increased by 100 million euros for the year 2022, 200 million euros for the year 2023 and 300 million euros as of the year 2024. Monthly monitoring of National and Regional Pharmaceutical Expenditure gennaio / settembre 2025 [2.29 Mb] [PDF] > gennaio / agosto 2025 [2.22 Mb] [PDF] > gennaio / luglio 2025 [2.23 Mb] [PDF] > gennaio / giugno 2025 [2.29 Mb] [PDF] > gennaio / maggio 2025 [1.49 Mb] [PDF] > gennaio / aprile 2025 [1.87 Mb] [PDF] > gennaio / marzo 2025 [1.64 Mb] [PDF] > gennaio / febbraio 2025 [1.43 Mb] [PDF] > January / December 2024 (Final balance) [1.32 Mb] [PDF] > January / December 2024 [1.63 Mb] [PDF] > January / November 2024 [1.13 Mb] [PDF] > January / October 2024 [1.41 Mb] [PDF] > January / September 2024 [2.06 Mb] [PDF] > January / August 2024 [1.48 Mb] [PDF] > January / July 2024 [1.52 Mb] [PDF] > January / June 2024 [1.55 Mb] [PDF] > January / May 2024 [1.27 Mb] [PDF] > January / April 2024 [1.3 Mb] [PDF] > January / March 2024 [1.32 Mb] [PDF] > January / February 2024 [1.21 Mb] [PDF] > National and Regional Trend in Pharmaceutical Expenditure Trend 2019 - 2022 [7.52 Mb] [PDF] > Trend 2019 - 2021 [5.66 Mb] [PDF] > Trend 2018 - 2020 [6.18 Mb] [PDF] > Monitoring of consumption and expenditure of medical gases January - December 2022 [1.12 Mb] [PDF] > January - December 2021 [0.59 Mb] [PDF] > Legislation Decree 15 July 2004 Law No. 135, 7 August 2012 Law No. 222, 29 November 2007 Archive Monitoring pharmaceutical expenditure - Archive Monitoring of biosimilars consumption and expenditure Monitoring of patent-expired non-biologic medicines Monitoraggio consumi e spesa Fattore VIII Monitoraggio delle Note AIFA Consumption and pharmaceutical expenditure The Medicines Utilization Monitoring Centre (OsMed) Governance of pharmaceutical expenditure Monitoring pharmaceutical expenditure Monitoring pharmaceutical expenditure - Archive Monitoring of biosimilars consumption and expenditure Monitoring of patent-expired non-biologic medicines Monitoraggio consumi e spesa Fattore VIII Monitoraggio delle Note AIFA Share Related links Electronic invoicing Marketing Authorisation Nested Applications Highlights 21/04/2026 - Medicine Use: 2024 Regional Reports Now Available Online 17/04/2026 - From one-size-fits-all treatments to personalised care: the revolution in precision medicine TUTTE LE NEWS - IN EVIDENZA ALL NEWS News 21/04/2026 Medicine Use: 2024 Regional Reports Now Available Online 15/04/2026 AIFA updates the Transparency Lists 13/04/2026 Medicine Shortage Communication on Endoxan (ciclofosfamide) All news Nested Applications Press From one-size-fits-all treatments to personalised care: the revolution in precision medicine All press releases Last tweets 📢 #AIFA comunica il calendario degli incontri nell’ambito delle iniziative dedicate al dialogo e al... Vai al post → 🔬 AIFA pubblica il dossier “Dalle terapie a taglia unica alle cure su misura: la rivoluzione della ... Vai al post → 🎙️ “Immagino un futuro in cui ciascuno di noi abbia un vero e proprio passaporto farmacogenetico, m... Vai al post → 💊 Quasi 4 cittadini su 10 hanno ricevuto almeno una prescrizione di #antibiotici nel 2024, con una ... Vai al post → ⚠️ Attenzione alle false cure miracolose Negli ultimi tempi si sta diffondendo un business pericol... Vai al post → #AIFA promuove l’ascolto e la trasparenza Approvati i Regolamenti di “AIFA Ascolta” e “AIFA Incontr... Vai al post → Go to Twitter profile Go to Twitter profile aifa_ufficiale Multimedia Medicina di precisione e appropriatezza prescrittiva Go to YouTube channel Cookie Bar Footer The agency Home Page FarmaciLine User participation and satisfaction Citizens' access Modulistica Open governance Acts of notification Legal notification TrovaNormeFarmaco Competition notices Tenders and contracts Contacts Via del Tritone, 181 00187 Roma Contacts Certified e-mail (PEC) contacts VAT number: 08703841000 Tax code: 97345810580 IPA AIFA code: aifa_rm IPA UCB code: UFE1TR FOLLOW US ON label.button.spotify Bluesky FEED RSS Feed Rss Cookie management Sezione Link Utili Legal notice Social Media Policy Dichiarazione di accessibilità Web accessibility Website statistics Online services go to beginning of content